Title: USE OF NITRIC OXIDE FOR THE TREATMENT OF AIRWAY CONstriction

Abstract: Use of inhalable nitric oxide (NO) in combination with a superoxide anion scavenger for the manufacture of a medicament for treating airway constriction in a mammal, especially man, said combination being used in a therapeutically effective amount to accomplish relaxation of said airway constriction. A method and a pharmaceutical preparation for the treatment of airway constriction while using the above-mentioned combination.
Use of nitric oxide for the treatment of airway constriction

Field of the invention

The present invention is within the field of medicaments for the treatment of airway constriction in a mammal, especially man. Particularly, the invention is convenient for enhancing the effect of nitric oxide treatment or producing an effect of nitric oxide in non-responders.

Background of the invention

showed great inter- and intra-individual variability, and some asthmatics were non responders with no improvement at all by nitric oxide (Högman M, Frostell CG, Hedenström H, Hedenstierna G. Am.Rev.Respir.Dis. 1993; 148:1474-1478).


Therefore the main problem behind this invention was to establish why the dilatory effect of nitric oxide on airways is generally reduced when the airway surface is exposed to hyperosmolarity. Based on the findings thereof a solution to said problem has now been found, viz. a
group of compounds having the ability of counteracting said reduced effect of nitric oxide.

Accordingly one object of the present invention is to provide suitable compounds to be used for relaxing the airways.

More specifically, the purpose of said compounds is to accomplish a relaxation of the airways.

Another object of the invention is to provide suitable compounds to be used to counteract reduced relaxing effects of nitric oxide when used alone, preferably for use in non-responders to nitric oxide alone.

A further object of the invention is to accomplish the use of a pure inhalable medicament.

Other objects of the invention should be apparent to a person skilled in the art after having read the description below.

**Summary of the invention**

The above-mentioned objects as well as other objects of the invention, which can be gathered by a person skilled in the art after having studied the description below, are accomplished by the use, method and pharmaceutical preparation defined in the accompanying claims.

More specifically, according to a first aspect of the invention there is provided a use of inhalable nitric oxide (NO) in the form of gaseous nitric oxide or of a
nitric oxide donor, in combination with a superoxide anion scavenger for the manufacture of a medicament for treating airway constriction in a mammal, especially man, said combination being used in a therapeutically effective amount to accomplish relaxation of said airway constriction.

Thus, according to the present invention it was surprisingly found that the reduced relaxing effect of exogenous nitric oxide, found in trachea subjected to intraluminal hyperosmolarity, is, at least partly, due to superoxide anions.


More specifically, it was found that when a scavenger of superoxide anions, in the form of a superoxide anion scavenger, was used in combination with a nitric oxide donor, the relaxing effect of the nitric oxide was potentiated, or the reduced effect of nitric oxide alone was reversed. In other words, the problem with poor response or non-response to nitric oxide treatment of airway constriction appears to be an inactivation of the nitric oxide molecule.

As to prior art in this respect, for instance the following can be referred to.

WO 96/39409 discloses compounds that oxidize and/or reduce superoxides. The compounds can be administered with nitric oxide or nitric oxide adducts. The compounds are useful for treating inflammatory disorders in mammals, particularly humans. Asthma is mentioned as one of many listed inflammatory disorders. However, there is no information of improved dilatory effect on the airways, i.e. asthma bronchiale is not referred to.

The use of superoxide ion scavengers for a medical purpose is also disclosed in WO 99/37616. However, the treatment disclosed relates to conditions associated with oxidative stress or endothelial dysfunction. Furthermore,
6 the effect referred to is intracellular. In other words, there are differences in kind between the two uses, respectively. Thus, the reference to asthma in a listing of conditions in WO 99/37616 relates to a condition associated with oxidative stress or endothelial dysfunction, which is the case in airway inflammation and vascular dysfunction disorders, respectively, and not to airway constriction as in the present invention. The present invention is not dependent on any endothelial dysfunction. Rather the effect seems to be an epithelial one. Furthermore, it is generally extracellular.

Endothelium-dependent activity of a superoxide anion scavenger is also referred to in Medline, accession No. 1999104010. Furthermore, said activity is disclosed in connection with lung transplantation only and is limited to a pulmonary vascular effect.

US 5,747,026 relates to a method of delivering antioxidants to cells and tissues. The compounds are delivered in pH-sensitive liposomes. This method of delivering antioxidants to tissues is said to, among other things, prevent vasospasm and pulmonary toxicity of diverse oxidants and preserve the action of nitric oxide. The experimental data provided only show that antioxidants per se exert a vascular relaxation effect in certain animal experiments. There are no data presented that antioxidants might strengthen the relaxing effect on airways of inhaled nitric oxide.

In Pediatr. Res. 1999; 45: 293 A there is disclosed a study of the effect of rhSOD and inhaled gaseous NO on pulmonary hypertension in a lamb model. However, there is
no suggestion whatsoever concerning any effects on the airways.

**Detailed description of the invention**

The combination of nitric oxide and a superoxide anion scavenger according to the present invention can be used for the manufacture of a medicament for treating all types of constriction challenges in the airways. Such constriction challenges can be the result of airway hyperreactivity, asthma and other conditions causing airway constriction.

A preferred embodiment of the present invention is in the manufacture of a medicament for treating airway constriction associated with asthma bronchiale, especially an acute condition of asthma bronchiale.

An especially preferable embodiment of the invention is represented by the treatment of a mammal who has been shown to be non-responding to inhalation of nitric oxide (gaseous or in the form of a donor) only. This embodiment is of significant clinical importance since within different patient groups treated with inhaled nitric oxide there is generally a large group of non-responders.

According to one embodiment of the invention nitric oxide is used in gaseous, inhalable form. Inhalation of gaseous nitric oxide may represent a great advantage in therapy, e.g. in comparison with a non-gaseous nitric oxide-donor, as the gas has no particles or droplets to disperse and transport to the respiratory tract. Gases have long free-diffusion pathways, easily bypass obstructions (such as
constricted airways), and dissolve directly in tissue without causing impaction bronchospasm. The beneficial effect of NO gas on bronchial smooth muscle tone is observed immediately following inhalation, making NO a useful first defense against bronchospasm that can be followed, if desired, by inhalation of longer-acting agents.

According to another embodiment of the invention, however, as defined above, the nitric oxide is administered in the form of a nitric oxide donor, i.e. a compound that act by releasing nitric oxide. Known nitric oxide releasing compounds useful in practice of the invention are nitroso or nitrosyl compounds such as S-nitroso-N-acetylpenicillamine, S-nitroso-L-cysteine and nitrosoguanidine, characterized by an -NO moitety that is spontaneously released or otherwise transferred from the compound under physiological conditions such as obtained in the lung. Other compounds are compounds in which NO is a ligand on a transition metal complex and as such is readily released or transferred from the compound under physiological conditions, e.g. nitroprusside, NO-ferredoxin, or an NO-heme complex. Further suitable nitrogen-containing compounds are compounds which are metabolized by enzymes endogenous to the respiratory and/or vascular system to produce the NO radical, e.g. arginine, glycerol trinitrate, isoamyl nitrite, inorganic nitrite, azide and hydroxylamine. Such types of nitric oxide releasing compounds and method for their synthesis are well known in the art. Preferably the nitric oxide donor is a compound that releases nitric oxide in such a way that only the airways and the pulmonary vessels are affected.
The nitric oxide donor used in the invention may be administered as a powder (i.e. finely divided solid, either provided pure or as a mixture with a biologically compatible carrier powder, or with one or more additional therapeutic compounds) or as a liquid (i.e. dissolved or suspended in a biologically compatible liquid carrier, optionally mixed with one or more additional therapeutic compounds), and can conveniently be inhaled in nebulized form (preferably including particles or droplets having a diameter of less than 10 \( \mu \text{m} \)). Carrier liquids and powders that are suitable for inhalation are commonly used in traditional asthma inhalation therapeutics and thus well known in the art. The optimal dosage range can be determined by routine procedures known to the skilled man.

The superoxide anion scavenger to be used in the invention can be any compound recognized as being suitable to mammalian, especially human, use, which can be conveniently administered. Said superoxide anion scavenger can be an enzyme having the ability of removing superoxide anions. Superoxide dismutase is a well known, widely distributed enzyme that is a preferred compound for the use according to the invention. The superoxide anion scavenger can, however, also be another compound having the ability of scavenging superoxide anions. Example of such compounds are antioxidants, e.g. vitamin E, vitamin C, bilirubin, urate, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, ethoxyquin and the trace element selenium.

The components used according to the invention can be administered by, commercially available, inhaler devices. Compressed NO gas may be obtained from a commercial sup-
plier, typically as a mixture of 200-2000 ppm NO in pure N₂ gas. Said NO-N₂ gas mixture may be delivered into the inhalation gas in an amount of 1-100000 nmol/min or, may be mixed with air, oxygen or another suitable carrier gas or gas mixture, generally to a concentration of 1 ppm to 180 ppm of said mixture. For inhalations during extended periods of time a range of 1-40 ppm is generally utilized, while 1-80 ppm or 1-180 ppm may be used for shorter periods of time, when an immediate strong effect is desired. Especially preferable ranges in the last-mentioned cases are 40-80 ppm or 40-180 ppm, respectively. As to further details concerning inhalation of NO reference is made to the prior art, e.g. EP 560 928 B1, the disclosure of which is hereby incorporated by reference, in this respect.

The nitric oxide and the superoxide anion scavenger can be administered sequentially in any order, or they can be administered simultaneously, in the latter case either with the two components from separate sources at the same time or together, or, in the form of a composition comprising both said nitric oxide and said superoxide anion scavenger.

The superoxide anion scavenger can be administered in the same manner as NO, i.e. by inhalation, but also by other common administration routes for pharmaceuticals. Among such routes reference can be made to sublingual, oral, and rectal administrations, application to epithelial surfaces, and injection, which may be subcutaneous, intramuscular, intravenous or intraperitoneal. Preferably, however, the superoxide anion scavenger is administered by inhalation. Thus it may be administered as a pow-
der (i.e. finely divided solid, either provided pure or as a mixture with a biologically compatible carrier powder, or with one or more additional therapeutic compounds) or as a liquid (i.e. dissolved or suspended in a biologically compatible liquid carrier, optionally mixed with one or more additional therapeutic compounds), but can conveniently be inhaled in nebulized form (preferably including particles or droplets having a diameter of less than 10 μm). Carrier liquids and powders that are suitable for inhalation are commonly used in traditional asthma inhalation therapeutics and thus well known in the art.

The superoxide anion scavenger is used in a therapeutically effective amount, such an amount being easily established by the skilled artisan, dependent inter alia on the type of compound used and the route of administration. As should be apparent to a person skilled in the art the term “therapeutic” in this respect as well as in general in the description and claims encompasses prophylactic treatment as well as treatment of an established condition. Furthermore, “therapeutically effective” is utilized in a sense that is common within this technical field, as is e.g. defined in EP 560 928 B1 referred to above, although in general in this specific case the superoxide anion scavenger is therapeutically effective as soon as it reverses a negative effect obtained when using nitric oxide only or enhances the effect of nitric oxide alone. However, as a guidance it can be added that for superoxide dismutase an effective dose range may for instance be 1 000-50 000 units per kg body weight (U/kg), 5 000-15 000 U/kg being a preferable range and 8 000-12 000 U/kg being especially preferred. For other superoxide anion scavengers similar scavenging effects can
easily be experimentally established by a person skilled in the art.

According to a second aspect of the invention a method is provided for the treatment of airway constriction in a mammal, especially man. Said method comprises administering to a mammal in need of such treatment, nitric oxide (NO), by inhalation, in combination with a superoxide anion scavenger, said combination being used in a therapeutically effective amount to accomplish relaxation of said airway constriction.

As to specific and preferable embodiments of said method reference is made to those specific and preferable embodiments which have been described in connection with the use according to the invention.

Finally, according to a third aspect of the invention, there is provided a pharmaceutical preparation for treatment of bronchoconstriction in a mammal, especially man, which comprises nitric oxide (NO) in combination with a superoxide anion scavenger, said nitric oxide and said superoxide anion scavenger being present in a therapeutically effective amount to accomplish relaxation of said airway constriction.

With reference to specific and preferable embodiments of said preparation reference is also made to said specific and preferable embodiments of the use according to the invention.

Brief description of the drawing
Fig. 1: Relaxation of carbachol-contracted (CCh) trachea by the nitric oxide donor sodium nitroprusside (SNP) after increasing the intraluminal osmolarity to 450 mOsm. Control group treated with hyperosmolarity before and during the experiment and group pretreated with 100 u/ml superoxide dismutase (SOD) on the extraluminal side. Values are per cent relaxation of CCh contracted trachea in mean ± s.e.mean. * significantly different from CCh.

The invention will now be illustrated by the following non-limiting examples:

**Example 1**

An in vitro guinea pig tracheal perfusion method was used to investigate the effect of superoxide dismutase (SOD), a scavenger of superoxide anions, on airway relaxation by the nitric oxide donor sodium nitroprusside (SNP) after elevating the osmolarity on the epithelial side with sodium chloride.

**MATERIAL AND METHODS**

**Perfused trachea preparation**

The experimental protocol was approved by the regional ethics committee on animal experiments. Male Dunkin Hartley guinea pigs (500-800 g) were given an overdose of pentobarbital (0.1 mg kg⁻¹ body weight intraperitoneally). The tracheas were rapidly dissected free of connective tissue, fat and blood vessels removed and mounted on a stainless steel perfusion holder. The perfusion system used was an improved version of Fedan & Frazer's system (Fedan JS, Frazer DG. Influence of epithelium on the
reactivity of guinea pig isolated, perfused trachea to bronchoactive drugs. J.Pharmacol.Exp.Ther. 1992; 262:741-750), described earlier by Munakata (Munakata M, Mitzner W, Menkes HA. Osmotic stimuli induce epithelial-dependent relaxation in the guinea pig trachea. J.Appl.Physiol. 1988; 64:466-471). After centrally fixed side-hole catheters were inserted into the lumen of the trachea from each end, the trachea was stretched to its in situ length and placed vertically in a 25 ml extraluminal organ bath containing Krebs-Henseleit buffer. The catheter at the inlet of the trachea, the proximal end, was connected to one side of a differential pressure transducer (P300D, Validyne Engineering Cooperation, CA., USA) and the outlet catheter at the distal end of the trachea was connected to the other side of the transducer. The inside of the trachea was perfused with Krebs-Henseleit buffer from the 25 ml intraluminal bath at 26 ml min⁻¹ in a recirculating loop. The Krebs-Henseleit buffer in both the extra- and intraluminal baths was kept at 37°C and bubbled with a gas mixture of 95% O₂ and 5% CO₂. The transmural pressure was adjusted to correspond to zero at baseline. Responses of the trachea were recorded by a computer (LabView 3.0 software, National Instruments Austin, TX, USA) using a specially designed program (kindly donated by Astra Draco, Lund, Sweden) adapted to the system.

Responses are expressed as the difference in pressure between proximal and distal recording sites (ΔP, cmH₂O).

Solutions and reagents
The modified isotonic Krebs-Henseleit buffer had an osmolarity of 290 mOsm, and was composed of (in mM):
NaCl, 117; NaHCO₃, 25; KH₂PO₄, 1.2; MgSO₄, 1.2; KCl, 4.7; CaCl₂, 2.5 and glucose, 1.03 (pH 7.4, 37°C). The hyperosmolar buffer was formed by increasing the NaCl concentration to 203 mM, which increased the osmolarity to 450 mOsm. Carbachol (Sigma Chemical Co, MO, USA) was dissolved in saline. The nitric oxide donor sodium nitroprusside (SNP, Sigma) and superoxide dismutase (SOD, from bovine liver, Sigma) was dissolved in Krebs-Henseleit buffer. SNP was protected from light until use.

Experimental protocol
All protocols started with an equilibration period of 60-75 min with washes every 15 min when both intraluminal and extraluminal solutions were replaced for fresh buffer. Thereafter the tracheas were subjected to one of the following protocols:

1) Control (n=6). The intra- and extraluminal buffers were isoosmolar and the trachea was contracted with 1 μM carbachol (CCh) applied extraluminally, corresponding to 50% maximum contraction (as determined in earlier experiments, data not shown). The CCh-contracted trachea was relaxed by the nitric oxide donor SNP, 3 mM added to the intraluminal bath. After a 60 min washout period, in which both the intra- and extraluminal buffer was replaced by fresh buffer every 15 min, the procedure was repeated.

2) Hyperosmolar buffer (n=6). Tracheas were contracted to 50% of maximum contraction by applying 1 μM carbachol extraluminally. The trachea was relaxed by the nitric oxide donor SNP 3 mM added to the intraluminal bath. After a 60 min washout period, the intraluminal buffer
was replaced by hyperosmolar buffer 10 min before the second carbachol contraction, then SNP was given to the trachea during hyperosmolar conditions.

3) Superoxide dismutase SOD (n=5). Tracheas were treated as the control group, with one addition to the protocol; SOD (100 units/ml) was applied to the extraluminal side of the trachea 10 min before the second provocation with CCh and SNP.

4) Hyperosmolar buffer and SOD. The enzyme superoxide dismutase (SOD) was used to investigate the effect of superoxide anions on the relaxing effect of SNP. After a first control challenge where 3 mM SNP was used to relax the CCh-contracted trachea, followed by a 60 min washout period, 100 u/ml SOD was applied to the extraluminal side of the trachea (n=8) 10 min before changing the intraluminal buffer to hyperosmolar buffer. The trachea was thereafter contracted with 1 μM CCh and the effect of 3 mM SNP was studied.

Statistics
Statistical analysis was performed with Statistica software (version 5.0, StatSoft. Inc., Tulsa, OK, USA). The results were analysed with Wilcoxon non-parametric matched pairs test and Mann-Whitney U-test where appropriate. For analysis between groups, Kruskal-Wallis ANOVA (analysis of variance) was used. Results are presented as mean values ± s.e.mean. A statistical result with P<0.05 was considered to be significant.
RESULTS

The initial CCh induced contraction of the trachea was of the same magnitude in the different groups studied (ns), and all groups relaxed on subsequent SNP (p<0.05) to the same level (ns). This was a control to see that all tracheas were viable and had the same initial prerequisites.

1) Control. CCh produced a contraction of the trachea by 1.49 ± 0.30 cmH2O, subsequent exposure to SNP relaxed the airway by 53.1 ± 6%, i.e. to 0.68 ±0.11 cmH2O (see figure 1).

2) Hyperosmolar buffer. After increasing the osmolarity of the intraluminal buffer to 450 mOsm, the CCh contraction was smaller (0.83 ± 0.17 cmH2O, p<0.05) than in normal conditions. When tracheas were subjected to intraluminal hyperosmolarity SNP relaxed the CCh-contracted trachea by 31 ± 7% (see figure 1). This was a significantly smaller percentual decrease than in the iso-osmolar control conditions (see control group, p<0.05) (see figure 1).

3) SOD. SOD had no effect on the baseline tone and there was no difference between SOD treated and untreated tracheas with respect to CCh contraction (SOD-treated: 1.36 ± 0.15 cmH2O; untreated see above: 1) control) or SNP relaxation (SOD-treated: 57 ±12%; untreated see above: 1) control) (see figure 1).

4) Hyperosmolar buffer and SOD. In tracheas pretreated with SOD before subjecting the intraluminal side to hyperosmolarity, SNP relaxed the trachea by 46 ± 5%, from 1.67 ± 0.29 to 0.92 ± 0.19 cmH2O. This relaxation
was not different from the relaxation of SOD pretreated tracheas in isoosmolar conditions, and it was a significantly larger relaxation than in tracheas subjected to hyperosmolar buffer not pretreated with SOD (p<0.05) (see figure 1).

Example 2

The results in the organ perfusion bath have also been reproduced in in vivo experiments. Thus, rabbits were anesthetized by intramuscular injection of the fluanisone and fentanyl citrate and by intravenous injection of diazepam and paralysed with pancuronium bromide. They were intubated and ventilated with a servo-ventilator (Siemens 900). The inspired oxygen fraction was 0.5. The animals were allocated to four different groups: 1/ Metacholine (MCh) group, exposed to an airway provocation of 1 mg MCh/ml; 2/ NO-MCh group where inhalation of 80 ppm NO was commenced before the MCh provocation and maintained for the remainder of the experiment; 3/ Hypertonic Saline (HS) - NO - MCh group, where hypertonic saline (3.6%) was nebulized into the airways followed by NO inhalation and MCh challenge; and 4/ SOD- HS- NO- MCh group where 8 000 U/kg of SOD was nebulized prior to the nebulization of HS and inhalation of NO, followed by the MCh challenge.

Measurements of respiratory resistance, calculated from airway pressure and gas flow recording, were calculated at baseline and after the MCh challenge in each group.
Results:

<table>
<thead>
<tr>
<th>Resistance (cm H2O/L/s)</th>
<th>BL</th>
<th>MCh</th>
<th>NO + MCh</th>
<th>HS + NO + MCh</th>
<th>SOD + HS + NO + MCh</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. BL</td>
<td>54 ± 4</td>
<td>161 ± 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. BL</td>
<td>50 ± 2</td>
<td></td>
<td>66 ± 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. BL</td>
<td>48 ± 2</td>
<td></td>
<td></td>
<td>190 ± 22</td>
<td></td>
</tr>
<tr>
<td>4. BL</td>
<td>47 ± 4</td>
<td></td>
<td></td>
<td>103 ± 15</td>
<td></td>
</tr>
</tbody>
</table>

BL: Baseline;

** = significant difference between BL and provocation (p<0.01)

T = significant difference between groups 3 and 4 after provocation (p<0.05)

Discussion: It can thus be seen that the rabbits react with a strong airway constriction on MCh challenge with a threefold increase in resistance (group 1). The NO inhalation prevented such increase (group 2) (a slight, non-significant increase was seen). Also, nebulization of HS into the airways abolished completely the effect of NO inhalation (group 3). Thus, the increase in resistance was of the same magnitude as in the first group, exposed solely to MCh. Finally, in the group receiving SOD by nebulization, the increase in resistance was blunted, despite that NO had been given after administration of hypertonic saline (group 4). Thus the increase in resistance was only half that seen the group exposed to hypertonic saline but not SOD.
The problem with non-responder phenomenon to inhaled nitric oxide has been investigated earlier. It was shown that hyperosmolarity on the epithelial side of the airway attenuates the effect of inhaled nitric oxide (Högman M, Hjoberg J, Hedenstierna G. Increased airway osmolarity inhibits the action of nitric oxide in the rabbit. Eur.Respir.J. 1998; 12:1313-1317) and that this is likely to be due to an inactivation of the nitric oxide molecule (Hjoberg J, Högman M, Hedenstierna G. Hyperosmolarity reduces the relaxing potency of nitric oxide donors in guinea-pig trachea. Br.J.Pharmacol. 1999; 127:391-396). According to the present example it was found that preventing the production of superoxide from guinea pig trachea subjected to an increased osmolarity on the epithelial side will increase the relaxation of the pre-contracted trachea by the nitric oxide donor sodium nitroprusside.
CLAIZS

1. Use of inhalable nitric oxide (NO), in the form of gaseous nitric oxide or a nitric oxide donor, in combination with a superoxide anion scavenger for the manufacture of a medicament for treating airway constriction in a mammal, especially man, said combination being used in a therapeutically effective amount to accomplish relaxation of said airway constriction.

2. Use according to claim 1, wherein said medicament is an inhalable medicament.

3. Use according to any one of claims 1-2, wherein said airway constriction is the result of an airway hyperreactivity or asthma.

4. Use according to claim 3, wherein said airway constriction is associated with asthma bronchiale.

5. Use according to claim 4, wherein said airway constriction is associated with an acute condition of asthma bronchiale.

6. Use according to claim 4, wherein said airway constriction is associated with status asthmaticus.

7. Use according to any one of claims 1-6, wherein said mammal is a non-responder to inhalation of nitric oxide or nitric oxide donor only.

8. Use according to any one of claims 1-7, wherein said manufacture relates to a medicament for sequential administration of said nitric oxide and said superoxide anion scavenger in any order.

9. Use according to any one of claims 1-7, wherein said medicament is in the form of a composition comprising said nitric oxide and said superoxide anion scavenger for simultaneous administration thereof.

10. Use according to any one of the preceding claims, wherein said superoxide scavenger is selected from
the group consisting of enzymes and antioxidants having
the ability of removing superoxide anions.

11. Use according to claim 10, wherein the superox-
ide anion scavenger is superoxide dismutase.

12. Use according to claim 11, wherein the dose of
superoxide dismutase is within the range of 1 000-50 000
U/kg, preferably 5 000-15 000 U/kg and most preferably 8
000-12 000 U/kg.

13. Use according to claim 10, wherein said superox-
ide scavenger is selected from the group consisting of
vitamin E, vitamin C, bilirubin, urate, butylated hydrox-
ytoluene, butylated anisole, propyl gallate, ethoxyquin
and selenium.

14. Use according to any one of the preceeding cla-
ims, wherein NO is present in said medicament in an
amount of 1-100 000 nmol/min.

15. Use according to any one of the preceeding cla-
ims, wherein the concentration of NO to be inhaled is
within the range of 1-180 ppm, preferably 1-80 ppm, espe-
cially 1-40 ppm, said NO being present in a carrier gas
or gas mixture.

16. Use according to any one of the preceeding cla-
ims, wherein said nitric oxide donor is selected from S-
nitroso-N-acetylpenicillamine, S-nitrosocysteine, nitro-
russide, nitrosoguanidine, glycerol trinitrate, isoamyl-
nitrite, inorganic nitrite, azide and hydroxylamine.

17. A method of treating airway constriction in a
mammal, especially man, which comprises administering
to a mammal in need of such treatment, nitric oxide (NO), in
the form of gaseous nitric oxide or a nitric oxide donor,
by inhalation, in combination with a superoxide anion
scavenger, said combination being used in a therapeuti-
cally effective amount to accomplish relaxation of said
airway constriction.

18. A method according to claim 17, wherein said su-
peroxide anion scavenger is also administered by inhala-
ation.
19. A method according to any one of claims 17 and 18, wherein said airway constriction is the result of an airway hyperreactivity or asthma.

20. A method according to claim 19, wherein said airway constriction is associated with asthma bronchiale, especially status asthmaticus or an acute condition of asthma bronchiale.

21. A method according to any one of claims 17-20, wherein said mammal is a non-responder to inhalation of nitric oxide or nitric oxide donor only.

22. A method according to any one of claims 17-21, wherein said nitric oxide and said superoxide anion scavenger are administered sequentially in any order.

23. A method according to any one of claims 17-21, wherein said nitric oxide and said superoxide anion scavenger are administered simultaneously.

24. A method according to any one of claims 17-23, wherein said superoxide anion scavenger is selected from the group consisting of enzymes and antioxidant having the ability of removing superoxide anions, especially vitamin E, vitamin C, bilirubin, urate, butylated hydroxytoluene, butylated snisole, propyl gallate, ethoxyquin and selenium.

25. A method according to claim 23, wherein said superoxide anion scavenger is superoxide dismutase.

26. A method according to claim 25, wherein the dose of superoxide dismutase is within the range of 1 000-50 000 U/kg, preferably 5 000-15 000 U/kg and most preferably 8 000-12 000 U/kg.

27. A method according to any one of claims 17-26, wherein said inhaled therapeutic amount of NO is 1-100 000 nmol/min or 1-180 ppm, preferably 1-80 ppm, especially 1-40 ppm, said NO being present in a carrier gas or gas mixture.

28. A method according to any one of claims 17-27, wherein said nitric oxide donor is selected from S-nitroso-N-acetylpenicillamine, S-nitrosocysteine, nitrop-
24

rsid, nitrosoguanidine, glycerol trinitrate, isoamyl-
nitrite, inorganic nitrite, azide and hydroxylamine.

29. Pharmaceutical preparation for treatment of air-
way constriction in a mammal, especially man, which com-
5 prises nitric oxide (NO), in the form of gaseous nitric
oxide or a nitric oxide donor, in combination with a su-
peroxide anion scavenger, said nitric oxide and said su-
peroxide anion scavenger being present in a therapeuti-
10 cally effective amount to accomplish relaxation of said
airway constriction.

30. Pharmaceutical preparation according to claim
29, for use as defined in any one of claims 2-16.
Figure 1. SNP induced relaxation of guinea pig trachea in percentage of CCh induced contraction in; control tracheas, tracheas subjected to intraluminal hyperosmolar buffer (HB), pretreated with superoxide dismutase (SOD), or subjected to intraluminal hyperosmolar buffer after pretreatment with SOD (HB + SOD), (* p<0.05).
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 38/44, A61K 33/00 // A61M 15/00, A61P 11/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 9937616 A1 (ÅNGGARD, ERIK), 29 July 1999 (29.07.99), page 2, line 1 - line 19; page 12, line 1 - line 32; page 21, line 15 - line 23, see abstract</td>
<td>1-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>--</td>
</tr>
<tr>
<td>A</td>
<td>US 5485827 A (WARREN M. ZAPOL), 23 January 1996 (23.01.96), page 6, column 2, line 1 - line 35</td>
<td>1-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td>--</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

| X | See patent family annex. |

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search: 9 March 2001

Date of mailing of the international search report: 12-03-2001

Name and mailing address of the ISA:
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Yvonne Siösteen/Eö
Telephone No. +46 8 762 25 00

Form PCT/ISA/210 (second sheet) (July 1998)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 9510185 A1 (DUKE UNIVERSITY), 20 April 1995 (20.04.95), page 29, line 1 - line 6</td>
<td>1-30</td>
</tr>
<tr>
<td>A</td>
<td>US 5873359 A (WARREN M. ZAPOL ET AL), 23 February 1999 (23.02.99)</td>
<td>1-30</td>
</tr>
</tbody>
</table>
**INTERNATIONAL SEARCH REPORT**

**Box I**  
Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: **17–28**  
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
   
   *see next sheet*

3. ☐ Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II**  
Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**  
☐ The additional search fees were accompanied by the applicant’s protest.

☐ No protest accompanied the payment of additional search fees.
Claims 17-28 relate to a method of treatment of the human or animal body or by therapy/ a diagnostic method practised on the human or animal body/ Rule 39.1 (iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the composition.
INTERNATIONAL SEARCH REPORT
Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 5873359 A</td>
<td>23/02/99</td>
<td>AT 158509 T</td>
<td>15/10/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 657726 B</td>
<td>23/03/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 9149891 A</td>
<td>08/07/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2097823 A</td>
<td>06/06/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 560928 T</td>
<td>22/09/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 786264 T</td>
<td>02/11/00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69127756 D,T</td>
<td>05/02/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 560928 T</td>
<td>01/12/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0560928 A,B</td>
<td>22/09/93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE 0560928 T3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0786264 A</td>
<td>30/07/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2082732 T</td>
<td>01/04/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2132043 T</td>
<td>16/08/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3024865 T</td>
<td>30/01/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 96300032 T</td>
<td>30/06/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 99300018 T</td>
<td>30/06/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2701978 B</td>
<td>21/01/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6504778 T</td>
<td>02/06/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10158175 A</td>
<td>16/06/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LV 12201 A,B</td>
<td>20/01/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 47527 A</td>
<td>17/04/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5485827 A</td>
<td>23/01/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5536241 A</td>
<td>16/07/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5570683 A</td>
<td>05/11/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9210228 A</td>
<td>25/06/92</td>
</tr>
</tbody>
</table>

Form PCT ISA 210 (patent family annex) (July 1998)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9937616 A1</td>
<td>29/07/99</td>
<td>AU 4120699 A</td>
<td>09/08/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7538298 A</td>
<td>08/12/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0981765 A</td>
<td>01/03/00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 9801398 D</td>
<td>00/00/00</td>
</tr>
<tr>
<td>US 5485827 A</td>
<td>23/01/96</td>
<td>AT 158509 T</td>
<td>15/10/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6577726 B</td>
<td>23/03/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 9149891 A</td>
<td>08/07/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2097823 A</td>
<td>06/06/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 560928 T</td>
<td>22/09/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 786264 T</td>
<td>02/11/00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69127756 D,T</td>
<td>05/02/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 560928 T</td>
<td>01/12/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0560928 A,B</td>
<td>22/09/93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE 0560928 T3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0786264 A</td>
<td>30/07/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2082732 T</td>
<td>01/04/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2132043 T</td>
<td>16/08/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3024865 T</td>
<td>30/01/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 9630032 T</td>
<td>30/06/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 99300018 T</td>
<td>30/06/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2701978 B</td>
<td>21/01/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6504778 T</td>
<td>02/06/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10158175 A</td>
<td>16/06/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LV 12201 A,B</td>
<td>20/01/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 47527 A</td>
<td>17/04/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5536241 A</td>
<td>16/07/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5570683 A</td>
<td>05/11/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5873359 A</td>
<td>23/02/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9210228 A</td>
<td>25/06/92</td>
</tr>
<tr>
<td>WO 9639409 A1</td>
<td>12/12/96</td>
<td>AU 6031096 A</td>
<td>24/12/96</td>
</tr>
<tr>
<td>WO 9510185 A1</td>
<td>20/04/95</td>
<td>AU 702596 B</td>
<td>25/02/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7976394 A</td>
<td>04/05/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2174236 A</td>
<td>20/04/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0723398 A</td>
<td>31/07/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9505805 T</td>
<td>10/06/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5747026 A</td>
<td>05/05/98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5994339 A</td>
<td>30/11/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6127356 A</td>
<td>03/10/00</td>
</tr>
</tbody>
</table>